In Vitro Validation of the S-303 Treatment System

All measured in vitro parameters of S-303 treated RBCs indicate suitability for transfusion. The Second Generation S-303 Treatment System for Red Blood Cells (RBCs) uses S-303 to crosslink nucleic acids, preventing replication of contaminating pathogens and residual leukocytes (Figure 1). Glutathione (GSH) is included to quench non-specific reactions. The S-303 Treatment System has been evaluated for compatibility with conventional blood banking practices at the Etablissement Francais du Sang (EFS), Alsace, Strasbourg, France in preparation for a Phase 3 clinical trial in cardiovascular surgery patients.